Drug intelligence / Profile preview

Accell 100

Development stage
Unknown
Lead developer
Integra LifeSciences
Administration
Topical
01

Overview

Accell 100 is a demineralized bone matrix (DBM) putty used as a bone graft substitute in orthopedic, spinal, and reconstructive surgeries. Developed by Integra LifeSciences, it is composed of 100% human-derived DBM without the addition of extrinsic carriers like glycerol or sodium hyaluronate. The product utilizes the proprietary Accell Bone Matrix (ABM) process, which provides a high concentration of naturally occurring Bone Morphogenetic Proteins (BMPs) and other growth factors. Its mechanism of action involves both osteoconduction, where the matrix serves as a scaffold for new bone growth, and osteoinduction, where the BMPs recruit and stimulate mesenchymal stem cells to differentiate into bone-forming osteoblasts. It is primarily indicated for filling bone voids or gaps that are not intrinsic to the stability of the bony structure.

Brand names
Accell 100Accell100Accell-100
Other names
Accell 100 DBMAccell100 DBMAccell-100 DBMDemineralized Bone Matrix
02

Targets

BMPR (Bone morphogenetic protein receptor)

Beyond the preview

Go deeper on Accell 100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accell 100.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call